Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.

A new dataset from humanized mice is shedding light on how two key immune proteins — IFN-α2 and IFN-β — trigger different responses across tissues and cell types. Using single-cell RNA sequencing, researchers found that IFN-α2 broadly activates more tissues, while the lung uniquely favors IFN-β. The findings could help explain the therapeutic effects and side effects of interferon-based treatments used in viral infections and multiple sclerosis.
Scientists have created a detailed new dataset using humanized mice to better understand how type I interferons (IFNs) — immune-signaling proteins used as treatments for viral infections and multiple sclerosis — affect specific cells and tissues throughout the body. Because human and mouse IFNs interact with their receptors differently, standard mouse studies don't always translate well to humans. To bridge that gap, researchers engineered mice with a humanized version of the type I IFN receptor, then treated them with IFN-α2 and IFN-β and used single-cell RNA sequencing to track gene expression changes across multiple tissues.
The results revealed striking differences between the two interferons. IFN-α2 triggered stronger, more widespread responses across more tissues, while the lung showed notably higher sensitivity to IFN-β. The team found that endothelial cells lining blood vessels drove tissue-specific responses in the lung, while interstitial macrophages were responsible for the differential responses between the two IFNs.
Key Takeaways:
Why it matters: This dataset gives researchers a powerful new tool to predict how interferon therapies will behave in humans — potentially helping clinicians better anticipate both the benefits and side effects of treatments for conditions like MS and viral infections.